FLORIDA — ULCERATIVE COLITIS: Ulcerative Colitis is a type of inflammatory bowel disease (IBD) that affects the lining of the large intestine (colon) and rectum. The cause of this disease is unknown. However, patients who have this disease generally have a weaker immune system. Stress and particular foods may trigger symptoms in those who possess this disease. The disease affects all age groups, but there have been peaks at ages 15-30 and then again at 50-70. The disease begins in the rectal area and can grow to infect the entire large intestine.
SYMPTOMS INCLUDE: The symptoms vary in intensity and could start suddenly or slowly. Half of patients experience mild symptoms while the other half gets the worse end. They include:
- Abdominal pain and cramping
- Weight loss
- Blood and pus in the stools
- Fever
- Light or extreme diarrhea
- Joint pain or swelling
AVALABLE TREATMENT:
- Diet and Nutrition- Certain types of foods may worsen diarrhea and gas symptoms. Eat small amounts of food, drink water, avoid high-fiber foods, limit milk products if you are lactose intolerant, and avoid fatty, greasy or fried foods and sauces.
- Stress- Stress increases when the disease is active because it results in an increase in the number of bowel movements a day and can be embarrassing.
- Surgery- Surgery to remove the colon will cure ulcerative colitis and removes the threat of colon cancer. Recommended for patients who have: Colitis that does not respond to complete medical therapy, changes in the lining of the colon that are thought to be precancerous, or serious complications such as rupture (perforation) of the colon, severe bleeding (hemorrhage) (Source: www.ncbi.nlm.nih.gov).
CHANGING LIVES: There are a number of medications available for patients with less severe cases. However, certain drugs can hinder the immune system, increase risk of colon cancer, or lead to infection. But, there is one new drug available that promotes healing, IP-10 or MDX-1100. It works by blocking a protein called chemokine so inflammation cannot occur. The drug has recently been filed with the FDA for approval. Preclinical studies demonstrate that antibodies targeting IP-10 neutralize the effects of IP-10 and decrease the appearance of the disease progression in animal models of ulcerative colitis and inflammatory bowel disease, as well as multiple sclerosis and rheumatoid arthritis. The Phase 2 trial is expected to enroll up to 106 patients at multiple centers internationally. Patients in the study are randomized to receive either placebo or MDX-1100 (10 mg/kg) every two weeks for a total of four doses. The primary endpoint of the study is response rate at eight weeks. (Source: www.drugs.com).
WFTV
